Skip to main content
ADIL
NASDAQ Life Sciences

ADIAL Completes Reverse Merger with Azora, Secures $25.3M Initial Financing, Faces Extreme Dilution

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$3.29
Mkt Cap
$7.053M
52W Low
$1.31
52W High
$18.9
52W Position info
151% above low
Off High info
83% below high
Rel. Volume info
37× avg
Market data snapshot near publication time

ADIL has more than doubled off its 52-week low of $1.31 on elevated volume (37× avg).

Summary

ADIAL Pharmaceuticals completed a reverse merger with Azora Therapeutics, securing an initial $25.3 million in financing, but at the cost of massive dilution and a change of control for existing shareholders.


Key Events · M&A and Partnerships · ADIL

  • Reverse Merger Completed

    ADIAL Pharmaceuticals acquired Azora Therapeutics, Inc. on June 11, 2026. This fundamentally shifts the company's business and pipeline.

  • Substantial Initial Financing Secured

    The company entered into a Securities Purchase Agreement with PIPE investors for an initial gross amount of $26.8 million, yielding approximately $25.3 million in net proceeds. This financing is critical given the company's prior 'going concern' warning.

  • Extreme Share Dilution

    The merger, assumed options, and initial/milestone warrants could result in the issuance of approximately 49.9 million new shares, representing over 2200% dilution relative to the current outstanding shares. The initial pre-funded warrants were priced at $2.7489, below the current market price of $3.29.

  • Change of Control

    Post-financing and note exchange, pre-Merger ADIAL equityholders will hold approximately 7.7% of the fully diluted common stock, while former Azora equityholders, noteholders, and PIPE investors will collectively hold over 92%.


Analysis · ADIL · Life Sciences

This filing details a transformative reverse merger where ADIAL Pharmaceuticals acquired Azora Therapeutics, effectively pivoting its business and addressing its prior 'going concern' warning. The transaction involves an initial capital raise of $25.3 million (net) from PIPE investors, with potential for an additional $26.8 million. However, this comes at an extremely high cost to existing shareholders, with potential dilution of over 2200% from the issuance of new shares and warrants. The former Azora equityholders and new PIPE investors will collectively hold the vast majority of the combined company, representing a significant change of control. While the financing provides a critical lifeline, the terms are highly unfavorable for current shareholders.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 52.1% of the 217 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ADIL was trading at $3.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.1M. The 52-week trading range was $1.31 to $18.90. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADIL - Latest Insights

ADIL
Nov 09, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.86
Real-time Price: $4.86 info
Change: $0 (0%) info
Market Cap: $13.261M info
ADIL
Oct 28, 2026, 5:56 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $5.08
Real-time Price: $4.86 info
Change: -$0.220 (-4%) info
Market Cap: $13.261M info
ADIL
Oct 28, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.86
Real-time Price: $4.86 info
Change: -$0.0036 (-0.07%) info
Market Cap: $13.261M info
ADIL
Oct 20, 2026, 8:25 PM EDT
Filing Type: 10-Q/A
Importance Score:
8
Price at Filing: $3.79
Real-time Price: $4.86 info
Change: +$1.07 (+28%) info
Market Cap: $13.261M info
ADIL
Sep 18, 2026, 5:18 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $4.86
Real-time Price: $4.86 info
Change: $0 (0%) info
Market Cap: $13.261M info